- Home
- AUDC vs NGNE Comparison
AUDC vs NGNE Comparison
Compare AUDC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- NGNE
- Stock Information
- Founded
- AUDC 1992
- NGNE 2003
- Country
- AUDC Israel
- NGNE United States
- Employees
- AUDC N/A
- NGNE N/A
- Industry
- AUDC Telecommunications Equipment
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- AUDC Utilities
- NGNE Health Care
- Exchange
- AUDC Nasdaq
- NGNE Nasdaq
- Market Cap
- AUDC 282.4M
- NGNE 325.3M
- IPO Year
- AUDC 1999
- NGNE N/A
- Fundamental
- Price
- AUDC $9.62
- NGNE $23.87
- Analyst Decision
- AUDC Buy
- NGNE Strong Buy
- Analyst Count
- AUDC 3
- NGNE 7
- Target Price
- AUDC $11.67
- NGNE $41.86
- AVG Volume (30 Days)
- AUDC 106.0K
- NGNE 218.5K
- Earning Date
- AUDC 11-05-2025
- NGNE 11-14-2025
- Dividend Yield
- AUDC 4.15%
- NGNE N/A
- EPS Growth
- AUDC 3.22
- NGNE N/A
- EPS
- AUDC 0.46
- NGNE N/A
- Revenue
- AUDC $243,249,000.00
- NGNE N/A
- Revenue This Year
- AUDC $2.52
- NGNE N/A
- Revenue Next Year
- AUDC $1.74
- NGNE N/A
- P/E Ratio
- AUDC $21.10
- NGNE N/A
- Revenue Growth
- AUDC N/A
- NGNE N/A
- 52 Week Low
- AUDC $7.70
- NGNE $6.88
- 52 Week High
- AUDC $12.72
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- AUDC 45.64
- NGNE 71.04
- Support Level
- AUDC $9.62
- NGNE $17.18
- Resistance Level
- AUDC $9.86
- NGNE $24.50
- Average True Range (ATR)
- AUDC 0.23
- NGNE 1.60
- MACD
- AUDC -0.04
- NGNE 0.76
- Stochastic Oscillator
- AUDC 21.50
- NGNE 84.73
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.